Prader-Willi syndrome is caused by a genetic disorder of chromosome 15. It is a rare disorder present at birth that results in a number of physical, mental, and behavioral problems. A key feature ...

Federal regulators are clearing a first-of-its-kind treatment for symptoms of a rare neurodevelopmental disorder that is ...

The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...

Diazoxide choline is the first drug indicated for hyperphagia in the rare genetic disorder. Prior to approval, people with ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

The FDA has approved the first therapy to address hyperphagia for children and adults aged 4 years and older with ...

Biotech Zafgen has ended development of its beloranib for the rare genetic condition Prader-Willi syndrome (PWS), sending its shares plummeting. CEO Thomas Hughes said in a letter to patients that ...

Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi ...

First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26 th, at 5:30pm ET REDWOOD CITY, Calif., March 26, ...

Vykat XR is specifically indicated to address hyperphagia, or the abnormally strong sensation of hunger, which often leads to ...

Credit: Solano Therapeutics. Vykat XR contains an extended-release formulation of diazoxide choline, the crystalline salt of diazoxide. Vykat XR is expected to be available in April 2025.